Patents by Inventor Rajendra TUMMALA

Rajendra TUMMALA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF FLARES IN LUPUS
    Publication number: 20240026015
    Abstract: The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE). The disclosure particular relates to the treatment of flares in SLE across multiple organ domains.
    Type: Application
    Filed: October 7, 2021
    Publication date: January 25, 2024
    Inventors: RUBANA KALYANI, GABRIEL ABREU, RAJENDRA TUMMALA, RICHARD FURIE, ERIC MORAND, ANCA ASKANASE, ED VITAL, KENNETH KALUNIAN, CATHARINA LINDHOLM, EMMANUELLE MAHO, CHRISTI KLEOUDIS
  • ANTI-IFNAR1 DOSING REGIME FOR SUBCUTANEOUS INJECTION
    Publication number: 20230365698
    Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.
    Type: Application
    Filed: April 21, 2023
    Publication date: November 16, 2023
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Sr., Joachim ALMQUIST, Thomas ROUSE
  • TREATMENT OF LUPUS NEPHRITIS
    Publication number: 20220348669
    Abstract: The disclosure relates to methods and compositions for the treatment of lupus nephritis. Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.
    Type: Application
    Filed: April 22, 2022
    Publication date: November 3, 2022
    Applicant: AstraZeneca AB
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE, Teodora TRASIEVA, Wendy WHITE, Dominic SINIBALDI, Madhu RAMASWAMY, Paul NEWCOMBE
  • DOSE
    Publication number: 20220340669
    Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.
    Type: Application
    Filed: April 22, 2022
    Publication date: October 27, 2022
    Applicant: AstraZeneca AB
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE